(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 May 2012 (24.05.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/068030 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2011/060661

(22) International Filing Date:
14 November 2011 (14.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/413,940 15 November 2010 (15.11.2010) US
61/421,462 9 December 2010 (09.12.2010) US

(71) Applicant *(for all designated States except US)*: **FIVE PRIME THERAPEUTICS, INC.** [US/US]; Two Corporate Drive, South San Francisco, California 94080 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **KEER, Harold** [US/US]; 230 Ferndale Way, Emerald Hills, California 94062 (US).

(74) Agent: **FORDIS, Jean B.**; Finnegan, Henderson, Farabow, Garrett & Dunner, 901 New York Avenue NW, Washington, D.C, District of Columbia 20001-4413 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) Title: TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS

Figure 1



(57) Abstract: The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.

WO 2012/068030 A1

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*